HLA Polymorphisms Influence the Development of Skin Rash Arising from Treatment with EGF Receptor Inhibitors

• Ullrich A , SchlessingerJ. Signal transduction by receptors with tyrosine kinase activity. Cell61(2) , 203–212 (1990).
   PubMed Web of Science ®Google Scholar
• Khazaie K , SchirrmacherV, LichtnerRB. EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev.12(3–4) , 255–274 (1993).
   PubMed Web of Science ®Google Scholar
• Petrelli F , BorgonovoK, CabidduM, BarniS. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell-lung cancer: a meta-analysis of 13 randomized trials. Clin. Lung Cancer13(2) , 107–114 (2012).
   PubMed Web of Science ®Google Scholar
• Moore MJ , GoldsteinD, HammJ et al; National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol.25(15) , 1960–1966 (2007).
   PubMed Web of Science ®Google Scholar
• Perez-Soler R , ChachouaA, HammondLA et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J. Clin. Oncol. 22 , 3238–3247 (2004).
   PubMed Web of Science ®Google Scholar
• Faehling M , EckertR, KuomS, KampT, StoiberKM, SchumannC. Benefit of erlotinib in patients with non-small-cell lung cancer is related to smoking status, gender, skin rash and radiological response but not to histology and treatment line. Oncology78 , 249–258 (2010).
   PubMed Web of Science ®Google Scholar
• Kris MG , NataleRB, HerbstRS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290 , 2149–2158 (2003).
   PubMed Web of Science ®Google Scholar
• Wacker B , NagraniT, WeinbergJ, WittK, ClarkG, CagnoniPJ. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large Phase III studies. Clin. Cancer Res.13 , 3913–3921 (2007).
   PubMed Web of Science ®Google Scholar
• Herbst RS , ArquetteM, ShinDM et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J. Clin. Oncol. 23 , 5578–5587 (2005).
   PubMed Web of Science ®Google Scholar
• Lenz HJ , Van Cutsem E, Khambata-Ford S et al. Multicenter Phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J. Clin. Oncol.24 , 4914–4921 (2006).
   PubMed Web of Science ®Google Scholar
• Cunningham D , HumbletY, SienaS et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351 , 337–345 (2004).
   PubMed Web of Science ®Google Scholar
• Moore MJ , GoldsteinD, HammJ et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25 , 1960–1966 (2007).
   PubMed Web of Science ®Google Scholar
• Xiong HQ , RosenbergA, LoBuglioA et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter Phase II Trial. J. Clin. Oncol. 22 , 2610–2616 (2004).
   PubMed Web of Science ®Google Scholar
• Segaert S , Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann. Oncol.16 , 1425–1433 (2005).
   PubMed Web of Science ®Google Scholar
• Agero AL , DuszaSW, Benvenuto-AndradeC, BusamKJ, MyskowskiP, HalpernAC. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J. Am. Acad. Dermatol.55 , 657–670 (2006).
   PubMed Web of Science ®Google Scholar
• Bianchini D , JayanthA, ChuaYJ, CunninghamD. Epidermal growth factor receptor inhibitor-related skin toxicity: mechanisms, treatment, and its potential role as a predictive marker. Clin. Colorectal Cancer7 , 33–43 (2008).
   PubMed Web of Science ®Google Scholar
• Perez-Soler R , SaltzL. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J. Clin. Oncol.23 , 5235–5246 (2005).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E . Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. Oncologist11 , 1010–1017 (2006).
   PubMed Web of Science ®Google Scholar
• Woodworth CD , MichaelE, MarkerD, AllenS, SmithL, NeesM. Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment. Mol. Cancer Ther.4(4) , 650–658 (2005).
   PubMed Web of Science ®Google Scholar
• Jeong HC , LeeSY, LeeEJ et al. Proteomic analysis of peripheral T-lymphocytes in patients with asthma. Chest 132(2) , 489–496 (2007).
   PubMed Web of Science ®Google Scholar
• Pichler WJ . Delayed drug hypersensitivity reactions. Ann. Intern. Med.139(8) , 683–693 (2003).
   PubMed Web of Science ®Google Scholar
• Hsieh MH , PattersonAE, KorngoldR. T-cell subsets mediate graft-versus-myeloid leukemia responses via different cytotoxic mechanisms. Biol. Blood Marrow Transplant.6(3) , 231–240 (2000).
   PubMed Web of Science ®Google Scholar
• Mallal S , PhillipsE, CarosiG et al; PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med.358(6) , 568–579 (2008).
   PubMed Web of Science ®Google Scholar
• Martin AM , NolanD, JamesI et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS 19(1) , 97–99 (2005).
   PubMed Web of Science ®Google Scholar
• Chantarangsu S , MushirodaT, MahasirimongkolS et al. HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenet. Genomics 19(2) , 139–146 (2009).
   PubMed Web of Science ®Google Scholar
• Chung WH , HungSI, HongHS et al. Medical genetics: a marker for Stevens–Johnson syndrome. Nature 428(6982) , 486 (2004).
   PubMed Web of Science ®Google Scholar
• Hung SI , ChungWH, LiouLB et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl Acad. Sci. USA102(11) , 4134–4139 (2005).
   PubMed Web of Science ®Google Scholar
• Parmar S , SchumannC, RüdigerS et al. Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity. Pharmacogenomics J. doi:10.1038/tpj.2011.51. (2011) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Schaid DJ , RowlandCM, TinesDE, JacobsonRM, PolandGA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am. J. Hum. Genet.70(2) , 425–434 (2002).
   PubMed Web of Science ®Google Scholar
• Maiers M , GragertL, KlitzW. High-resolution HLA alleles and haplotypes in the United States population. Hum. Immunol.68(9) , 779–788 (2007).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Galarza FF , ChristmasS, MiddletonD, JonesAR. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res.39(Database issue) , D913–D919 (2011).
   PubMed Web of Science ®Google Scholar
• Parker KC , BednarekMA, HullLK et al. Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2. J. Immunol. 149(11) , 3580–3587 (1992).
   PubMed Web of Science ®Google Scholar
• DiBrino M , ParkerKC, ShiloachJ et al. Endogenous peptides bound to HLA-A3 possess a specific combination of anchor residues that permit identification of potential antigenic peptides. Proc. Natl Acad. Sci. USA 90(4) , 1508–1512 (1993).
   PubMed Web of Science ®Google Scholar
• Pollack BP , SapkotaB, CarteeTV. Epidermal growth factor receptor inhibition augments the expression of MHC class I and II genes. Clin. Cancer Res.17(13) , 4400–4413 (2011).
   PubMed Web of Science ®Google Scholar
• Alper CA , LarsenCE, DubeyDP, AwdehZL, FiciDA, YunisEJ. The haplotype structure of the human major histocompatibility complex. Hum. Immunol.67(1–2) , 73–84 (2006).
   PubMed Web of Science ®Google Scholar
• Danke NA , KoelleDM, YeeC, BeherayS, KwokWW. Autoreactive T cells in healthy individuals. J. Immunol.172(10) , 5967–5972 (2004).
   PubMed Web of Science ®Google Scholar
• Xia G , TruittRL, JohnsonBD. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras. Biol. Blood Marrow Transplant.12(4) , 397–407 (2006).
   PubMed Web of Science ®Google Scholar
• Copelan EA , PenzaSL, ElderPJ et al. Influence of graft-versus-host disease on outcome following allogeneic transplantation with radiation-free preparative therapy in patients with advanced leukemia. Bone Marrow Transplant. 18(5) , 907–911 (1996).
   PubMed Web of Science ®Google Scholar
• Hiraki A , FujiiN, MurakamiT et al. High frequency of allele-specific down-regulation of HLA class I expression in lung cancer cell lines. Anticancer Res. 24(3a) , 1525–1528 (2004).
   PubMed Web of Science ®Google Scholar
• Pandha H , RiggA, JohnJ, LemoineN. Loss of expression of antigen-presenting molecules in human pancreatic cancer and pancreatic cancer cell lines. Clin. Exp. Immunol.148(1) , 127–135 (2007).
   PubMed Web of Science ®Google Scholar

▪ Website

• Cancer Therapy Evaluation Program Common Toxicity Criteria. http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf.
   Google Scholar